GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Wednesday, March 6, 2024 | |||||
Time: | 1:30 – 2:00 p.m. Eastern Standard Time (EST) | |||||
Location: | Boston Marriott Copley Place in Boston, Massachusetts | |||||
Moderator: | Brendan Smith, Ph.D., Vice President, Biotechnology Equity Research | |||||
Novavax participant: | John Jacobs, President and Chief Executive Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, March 6, 2024 | |||||
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.40 |
| Daily Change: | -0.15 -1.99 |
| Daily Volume: | 3,814,881 |
| Market Cap: | US$1.200B |
May 19, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
